Abstract. In recent years, a large number of studies have shown that the abnormal expression of long non-coding (lnc)RNAs can lead to a variety of different diseases, including inflammatory disorders, cardiovascular disease, nervous system diseases, and cancers. Recent research has demonstrated the biological characteristics of lncRNAs and the important functions of lncRNAs in oral inflammation, precancerous lesions and cancers. The present review aims to explore and discuss the potential roles of candidate lncRNAs in oral diseases by summarizing multiple lncRNA profiles in diseased and healthy oral tissues to determine the altered lncRNA signatures. In addition, to highlight the exact regulatory mechanism of lncRNAs in oral inflammatory disorders, potentially premalignant oral epithelial lesions and oral squamous cell carcinoma. The detection of lncRNAs in oral samples has the potential to be used as a diagnostic and an early detection tool for oral diseases. Furthermore, lncRNAs are promising future therapeutic targets in oral diseases, and research in this field may expand in the future.

1. Introduction
Oral inflammatory disorder is a series of processes associated with microbial infections (such as periodontal, endodontic and periapical diseases) and immune-mediated damage [for example Sjögren's syndrome (SS)] (1). Numerous factors, including non-coding (nc)RNAs, leukocytes, cytokines and complement components, are involved in this process (2,3). Long non-coding (Inc)RNAs affect oral inflammation by sponging microRNAs (miRNA/miR) (4) or activating downstream target miRNAs (5). Research on competing endogenous (ce)RNA mechanisms, in which lncRNAs sponge specific miRNAs to suppress their target genes, has increased in number over the last 2 years (6). For example, lncRNA metastasis associated lung adenocarcinoma transcript 1 (MALAT1) acts as a sponge of miR-20a to induce Toll-like receptor 4 (TLR4) signaling and results in an inflammatory reaction from human gingival fibroblasts (HGFs) (7).

Several potentially premalignant oral epithelial lesions (PPOELs) are associated with the disease process of chronic inflammatory disorders (8,9). PPOEL is a broad term to define both histological and clinical oral lesions that have malignant potential, including oral lichen planus (OLP), oral submucous fibrosis (OSF), and oral dysplasia (10). In addition, other vital epigenetic and subcellular regulatory non-coding transcripts, such as lncRNAs and miRNAs are also known to regulate the mRNA expression of inflammation-related cytokines, and disturbance of the miRNA-mRNA-cytokine regulatory network is one of the common pathological features of PPOELs (11,12). For example, the significant upregulation of miR-31 and downregulation of its target gene, C-X-C motif chemokine ligand 12 (CXCL12) contributed to progression of PPOELs (13).

As the 7th hallmark of cancer, chronic inflammation has been linked to various stages of tumorigenesis (14). Several studies have reported that numerous regulators, including inflammatory cytokines and ncRNAs, facilitate tumor development (15,16). LncRNAs participate in the transformation of chronic inflammation into cancer by altering the expression of various inflammatory signaling pathways such as NF-kB and STAT3 and proinflammatory cytokines [such as tumor necrosis factor (TNF) family]. Interleukin (IL)-6-dependent STAT3 signaling activation contributes to the occurrence of colorectal cancer (17). The major histological type of oral cancer is oral...
squamous cell carcinoma (OSCC) (18). Jia et al (19), identified that differentially expressed (DE) IncRNAs and genes between OSCC, oral dysplasia, and normal oral tissues may control the initiation and development of OSCC through phosphatidylinositol-3-kinases (PI3K)/Akt signaling and mast cell NF-κB functional pathways.

IncRNAs play an essential role in the occurrence and development of inflammation and cancer (20,21). The oral diseases associated with the function of IncRNAs are shown in Fig. 1. According to previous reports, the DE IncRNAs between healthy and pathological oral tissues may affect the occurrence and process of oral diseases (Table I). The present review outlines the current understanding of the established functions and underlying mechanisms of IncRNAs in various oral inflammatory disorders, PPOELs and OSCC.

2. IncRNA biogenesis

IncRNAs are a class of RNA molecules whose transcript length is >200 nucleotides (22). Different IncRNA classifications have been established based on different criteria. The first criteria was presented by Jarroux et al (23), and IncRNAs which are >10 kb belong to the groups of very long intergenic RNAs and macro IncRNAs. Examples of macro IncRNAs include antisense of IGF2R non-protein coding RNA, KCNQ1 opposite strand/antisense transcript 1 and GNAS antisense RNA1, which act as cis-silencers in mouse genomic imprinting (24). The second criterion, location with respect to protein coding genes, is commonly used. In this classification, 5 types (sense, antisense, bidirectional, intronic and intergenic) of IncRNAs are included (23). An example of nature antisense transcripts, which is one type of antisense IncRNAs, is antisense non-coding RNA in the INK4 locus, which is encoded by the NK4b-ARF-INK4a locus on chromosome 9p21 (25).

IncRNAs also function as ceRNAs (competing endogenous RNAs), one type of SAL, modulates chromatin structure in cis and increases gene expression in trans at the INK4 locus, which encodes cell cycle inhibitors, that are important to senescence-associated cell proliferation arrest (35). The schematic diagram illustrating various classes of IncRNAs are presented in Fig. 2.

IncRNA can also be classified according to their function. IncRNAs exert or execute their functions in four main ways: Signal, decay, guide, and scaffold. They have been shown to impact cell macromolecular (protein, RNA and DNA) stability (36). The regulatory mechanism of IncRNAs vary based on their locations within the cells. They participate in chromatin modification and transcription in the nucleus, while they interact with RNA-binding proteins or modulate mRNA translation in the cytoplasm (37,38). There are a variety of mutual regulatory mechanisms for IncRNAs and miRNAs. IncRNAs can not only be mediated by miRNAs but also act as miRNA precursors. It is noteworthy that the ceRNA network is one of the common sites of posttranscriptional regulation (12). In the last 5 years, it has been demonstrated that IncRNAs are important in the regulation of a healthy immune system, which in turn is important for healthy oral tissue (39,40,41). An increasing number of IncRNAs have been reported to regulate the differentiation and activation of immune cells. The differentiation of granulocytes is partly mediated by HOX antisense intergenic RNA myeloid 1 (HOTAIRM1), an antisense IncRNA within the HOXA gene locus. Hallmark myeloid maturation-associated genes such as HOXA1/A2 would be inhibited by silencing HOTAIRM1 (42). The potential importance of IncRNAs in the immune response, inflammation and even cancers is emerging (43-45).

3. Role of IncRNAs in oral inflammatory disorders

Pulpitis. Pulpitis is a state of inflammation of the dental pulp. Most cases are due to penetration of a carious lesion into the pulp chamber (46). Pulpitis is classified as either reversible or irreversible (47). Huang and Chen (48) conducted a microarray analysis to establish IncRNA profiles of inflamed (n=7) and normal (n=5) pulp tissues. A total of 752 IncRNAs (338 upregulated and 414 downregulated) were significantly expressed. A total of 460 significantly upregulated genes were enriched in biological processes, such as immune system processes, immune and defense response, the response to stress, and cell activation. The results indicated that most IncRNAs might play roles in the immune system and inflammatory responses of dental pulp. Lei et al (49), performed a comprehensive analysis of a IncRNA-miRNA-mRNA ceRNA network by integrating the IncRNA profile from Huang and Chen (48), the miRNA profile from Zhong et al (50) and the gene expression profile from Galicia et al (51). A ceRNA regulatory network was created, which was composed of the IncRNA
plasmacytoma variant translocation 1, miR-455-5p, and the mRNAs, suppressor of cytokine signaling 3 and Plexin C1. To the best of our knowledge, only one lncRNA microarray has been performed with a comprehensive analysis (49). There has been no mechanistic study focusing on specific lncRNAs in pulpitis. Thus, more research is required to explore the regulatory role of specific lncRNAs in pulpitis.

Periodontitis. Periodontitis is an inflammatory disease, which is primarily caused by bacterial infection (52). It can cause inflammation of the gingivae, loss of alveolar bone and loss of attachment (53). Tooth loss, which occurs in adults is largely due to periodontitis (54). In 2015, Zou et al (55) revealed for the first time that lncRNAs have critical roles in the pathogenesis of periodontitis. A total of 2 pairs of chronic periodontitis gingival samples and adjacent healthy samples were collected for lncRNA analysis and 8,925 DE lncRNAs were detected, of which 4,313 were upregulated and 4,612 were downregulated. Functional analysis of the nearby protein-coding genes revealed that different lncRNAs can regulate a common gene, and a single lncRNA can be regulated by different genes. Thus, lncRNAs might play crucial and dual roles in periodontitis.

Chen et al (4) found that lncRNA FGD5 antisense RNA1 (FGD5-AS1) was downregulated in the gingival samples from patients with chronic periodontal disease compared with that in healthy samples. FGD5-AS1 inhibited NF-κB signaling via the FGD5-AS1/miR-142-3p/Suppressor of cytokine signaling 6 (SOCS6) ceRNA network and subsequently reduced the secretion of TNF-α, IL-6, IL-1β and IL-8. Thus, the axis may provide a promising strategy for the treatment of periodontitis.

Several lncRNAs inhibit periodontitis; however, results from recent research have revealed that lncRNAs could promote the inflammatory process of periodontal-derived cells, including MALAT1 (7) and papillary thyroid carcinoma susceptibility candidate 3 (56). Li et al (7), explored the role of MALAT1 in inflammatory cytokine production in HGFs. The study indicated that MALAT1 bound to miR-20a, as a ceRNA and consequently led to increased mRNA levels of TLR4, which contributed to the activation of inflammation. Therefore, the effect and mechanism of MALAT1 in periodontal inflammation have been characterized.

SS. SS is a chronic systemic autoimmune disease characterized by reduced secretions of the salivary and lacrimal glands and associated neuroendocrine disturbances (57). The disturbances of neuroendocrine include release of hormones (i.e., glucocorticoids) via the hypothalamic-pituitary-adrenal axis stimulation, production of mediators within the sympathetic innervation of immune organs (i.e., thymus) and production of proinflammatory cytokines (i.e., IL-2 and TNF-α) during the inflammatory response (58). The primary hallmark of SS is the infiltration of inflammatory mediators and cells, particularly T and B cells into the salivary and lacrimal glands (59). In addition, gland tissues have damaged acinar cells, fibrosis and increased adiposity with severe inflammatory lesions (60,61). Therefore, exploration into the relevant molecular mechanisms underlying SS is required.

In 2019, Dolcino et al (62) performed a high-throughput gene and lncRNA expression profiling in peripheral blood mononuclear cell samples from 8 patients with primary SS (pSS) and 8 healthy subjects. Among the 199 lncRNAs that were identified, CTD-2020K17.1, LINC00511 and LINC00657 and their target genes were found to be involved in apoptosis, immune response, cell proliferation, and several proinflammatory pathways. Shi et al (63), compared the expression profiles of lncRNAs from labial salivary glands between patients with pSS and healthy individuals. The gene ontology and pathway analysis results found 28 DE mRNAs associated with 8 DE lncRNAs were involved in chemokine signaling pathways, the NF-κB signaling pathway, and the TNF signaling pathway. Taken together, the results suggest that samples from multiple tissues could be utilized for investigating the same oral autoimmune disease. A comparison of DE lncRNA sets from different sample types of the same disease could provide valuable clues to the discovery of novel therapeutic targets to treat oral autoimmune diseases.

Subsequently, Xin et al (5) demonstrated that lncRNA myocardial infarction associated transcript 2 (Mirt2) reduces apoptosis and inflammatory levels in interferon (IFN)-γ-induced inflammation in salivary gland epithelial cells. It is hypothesized that Mirt2 might block NF-κB, and Janus kinase (JAK)/STAT3 signaling by increasing miR-377 expression levels.
| Disease          | No. of sample/subjects                                                                 | Method            | Confirmation                                                                 | Findings                                                                 | Comments                                                                 | (Refs.) |
|------------------|----------------------------------------------------------------------------------------|------------------|------------------------------------------------------------------------------|--------------------------------------------------------------------------|-------------------------------------------------------------------------|---------|
| Pulpitis         | 7 inflamed pulp tissues and 5 healthy pulp tissues                                      | Microarray       | RT-qPCR; 10 normal human pulp tissue and 10 inflamed samples                | 338 upregulated and 414 downregulated lncRNAs; FC>2; P<0.05             | Inflamed pulp samples were collected from patients with pulpitis, to reflect the real pathological state | (31)    |
| Periodontitis    | Inflamed and healthy adjacent gingival tissue from two patients with chronic periodontitis | Microarray       | RT-qPCR; 15 normal tissue samples and 30 chronic periodontitis tissue samples | 4313 upregulated and 4612 downregulated lncRNAs; FC≥2.0; P≤0.05          | First time to analyze DE lncRNAs between chronic periodontitis tissues samples and adjacent normal tissues | (36)    |
| SS               | PBMCs from 8 patients with pSS and 8 healthy subjects                                  | Microarray       | qRT-PCR; No sample size reported                                             | 199 dysregulated lncRNAs; FC≥1.5; P≤0.01 ¹                          | No validation; first time to analyze DE lncRNAs in PBMCs of pSS          | (43)    |
| SS               | LSGs from 4 pSS patients and 4 healthy individuals                                     | Microarray       | RT-qPCR; 30 pSS patients and 16 controls                                    | 890 upregulated lncRNAs and 353 downregulated lncRNAs; FC>2; P<0.05    | First time to analyze DE lncRNAs in LSGs of pSS                         | (44)    |
| OSF              | 20 OSCC samples, 10 OSF samples and 13 normal mucous samples                           | RNA-sequencing   | RT-qPCR; 20 OSCC samples, 10 OSF samples and 13 normal mucous samples      | 231 upregulated lncRNAs and 456 downregulated lncRNAs; FC>2; P<0.05    | LncRNAs involved in the malignant transformation process were firstly analyzed and assessed | (56)    |
| OLP              | 1 papillomavirus-related OSCC tissue, one OLP tissue and 1 normal oral mucosa tissue samples | RNA-sequencing   | -                                                                            | 76.2% intergenic lncRNAs and 16.5% sense lncRNAs; A coding potential calculator score <0, and CPAT probability ≤0.364 | 3 types of tissues samples but sample numbers were too small; lncRNAs involved in the malignant transformation process were firstly analyzed and assessed | (70)    |
| OSCC             | 72 OSCC tissues and adjacent normal tissues                                            | Microarray       | RT-qPCR; 72 OSCC tissues and adjacent normal tissues                        | 933 upregulated and 1361 downregulated lncRNAs; FC>2.0; P<0.05         | 3 types of OSCC tissues (tongue cancer, gingival carcinoma and carcinoma of the bucal mucosa) were analyzed and compared, and 4 critical lncRNA nodes were identified | (62)    |

¹Bonferroni corrected P-value. lnc, long non-coding; SS, Sjögren's syndrome; pSS, primary SS; OSCC, oral squamous cell carcinoma; OLP, oral lichen planus; OSF, oral submucous fibrosis; PBMCs, peripheral blood mononuclear cells; LSGs, labial salivary glands; RT-qPCR, reverse transcription-quantitative PCR; FC, fold change; CPAT, Coding Potential Assessment Tool; DE, differentially expressed.
Research investigating IncRNAs typically involves the fields of medicine and biology; however, research regarding IncRNAs in oral inflammatory disorders is still in the early stages. To date, the collection of clinical oral tissue samples...
and subsequent microarray or sequencing analysis has been the primary method of investigation in this field. In periodontitis, the majority of lncRNAs serve as ceRNAs (4,6,7). There are a high number of research models investigating oral tissue-derived cells treated with related inflammatory stimuli (i.e., lipopolysaccharide and IFN-γ) (5,7). Periodontitis animal models and lncRNAs have been well-established (64-66), while animal models involving lncRNAs in other oral inflammatory disorders requires further investigation. Thus, additional research is required to determine the mechanism of lncRNAs in oral inflammatory disorders.

4. Role of lncRNAs in PPOELs

OSF. OSF is a chronic, occult oral mucosal disease associated with chewing betel nut, characterized by a juxta-epithelial inflammatory response followed by generalized submucosal fibrosis (67,68). As a result, OSF typically leads to difficulty in opening the mouth and an increased malignant transformation rate (69,70). Therefore, the identification of molecules associated with OSF pathological progression is urgent. In the course of OSF, endothelial dysfunction may be accompanied by the dysregulation of multiple lncRNAs (71). For example, lncRNA growth arrest specific 5 antisense RNA 1 (GAS5-AS1) was inhibited, while lncRNA hypoxia-inducible factor 1-α antisense RNA 1 (HIF1A-ASI) was upregulated during the development of OSF (72,73). Research into lncRNAs has increased in the last 5 years; however, the function of numerous lncRNAs in OSF remains unclear. To date, only four articles have illustrated the relative issues (72-75).

The lncRNA sequencing conducted in 2019 by Zhou et al (75) included 13 normal mucous samples, 10 OSF samples, and 20 OSCC samples. A total of 5 DE candidate lncRNAs were found to participate in the inflammatory signaling pathway and contributed to inflammatory and fibroelastic pathogenetic changes by deregulating their cis-target and trans-target genes in OSF malignant development. Further functional analysis of these lncRNAs is required to provide conclusive evidence supporting an underlying regulatory mechanism during OSF.

Fang et al (74), determined that arecoline-induced myofibroblast trans-differentiation occurred via LINC00974-mediated activation of the transforming growth factor-β (TGF-β)/Smad signaling pathway. According to their study, collagen gel contractility and myofibroblast migration ability was increased in fibrotic buccal mucosal fibroblasts (fBMFs) overexpressing LINC00974. Increased expression of another lncRNAHIF1A-ASI also positively modulates the TGF-β/Smad signaling pathway, similar to LINC00974 (72). However, the lncRNA GASS-ASI presented contrary results in arecoline-treated BMFs and fBMFs (73).

OLP. OLP is a chronic inflammatory disease affecting the oral mucosa with characteristic relapses and remissions (76-78). Emerging evidence shows that OLP may be premalignant (79). Unstable molecular changes can induce the production of several inflammatory cytokines and subsequently contribute to the course of OLP (77,80). For example, pathogen-associated molecular patterns and adaptor molecules (i.e., myeloid differentiation factor 88) activation leads to nuclear translocation of NF-κB and augments the transcription of inflammatory genes (i.e., IL-6 and IL-8) (81). As with OSF, there have only been two studies on the role of lncRNAs in OLP to date.

Yang et al (82), examined DE genes and lncRNA targets in human papillomavirus-related OSCC (n=1), normal (n=1), and OLP (n=1) samples. Of the identified lncRNAs, most (697; 76.2%) were intergenic lncRNAs, followed by 151 sense lncRNAs (16.5%). Keratinization and MHC class I antigen processing and presentation were significantly enriched by OSCC-associated DE genes and lncRNA targets, and the olfactory transduction pathway was enriched by OLP- and OSCC-related DE genes. To the best of our knowledge, this has been the only study investigating the lncRNA profile of OLP so far; however, the number of tissue samples was too small to guarantee the validity of these findings. In addition, there is evidence suggesting that lncRNA DQ786243 significantly enhances the expression levels of miR-146a by inducing Forkhead box P3 (Foxp3), which subsequently blocks NF-κB signaling during OLP. Moreover, Foxp3+ regulatory T cells significantly suppressed the function of other CD4+ T cells, such as CD4+IL-17+ helper T cells and CD4+IL-17+ helper T cells, by inhibiting the mRNA expression levels of IFN-γ and IL-17 (83).

LncRNA microarray analysis is considered a reasonable option for comparing and determining DE lncRNAs in normal, PPOEL and OSCC tissues, which are difficult to simultaneously acquire in one patient. Animal models which investigate both lncRNAs and PPOELs are expected to be explored extensively, and to primarily include fBMFs treated with related stimuli (i.e., arecoline). Mechanistically, the classical signaling pathways in PPOELs focus on the TGF-β/Smad signaling pathways. Therefore, it is worth exploring more regulatory mechanisms (i.e., p38/MAPK and JAK/STAT3 signaling pathways) in subsequent studies on PPOELs.

5. Role of lncRNAs in OSCC

Oral cancers are cancers that exist in the oral cavity, such as the mucosal surfaces of the lips, floor of the mouth, tongue, buccal mucosa, lower and upper gingival surfaces, hard palate, and retromolar trigone (84). The histology of oral cancers varies widely; the majority of them are OSCCs (84). An increasing number of reports have revealed that lncRNAs play a broad role in the oncogenesis and progression of OSCC through transcriptional regulation, posttranscriptional modulation and epigenetic modifications (85). LncRNAs, functioning in oral cancer migration, epithelial-mesenchymal transition (EMT), metastasis, progression and invasion (86), could serve as biomarkers or therapeutic targets for OSCC diagnosis, prognosis and treatment (87).

With the development of whole transcriptome analyses, including serial analyses of gene expression, RNA sequencing and microarray data, several oral cancer-associated lncRNAs have been identified. In 2019, Qiu et al (88) screened 2,294 DE lncRNAs (933 upregulated and 1,361 downregulated) in OSCC tissues (n=72) compared with paired adjacent normal tissues. A total of four lncRNA-mRNA coexpression networks were constructed, and low expression levels of the four lncRNA nodes contributed to poor median progression-free survival and overall survival. This study provided novel insights into the role of lncRNAs in OSCC.
Table II. Regulatory effect of lncRNAs in oral inflammatory disorders, PPOELs and OSCC.

| lncRNA     | Cell category | Cell stimulation (bacteria) | Disease       | Effects                                                                 | Modes of action | Associated targets or pathways                  | (Refs.) |
|------------|---------------|-----------------------------|---------------|------------------------------------------------------------------------|-----------------|-------------------------------------------------|---------|
| FGD5-AS1   | PDLCs         | LPS (P. g)                  | Periodontitis | Inhibit apoptosis and reduce inflammatory cytokine production          | Sponging miR-142-3p | SOCS6 and NF-κB                                 | (37)    |
| MALAT1     | HGFs          | LPS (P. g or E. coli)       | Periodontitis | Enhance cytokine production                                            | Sponging miR-20a | TLR4                                            | (7)     |
| Mirt2      | SGECs         | IFN-γ                       | SS            | Repress apoptosis                                                      | Facilitate miR-377 and enhance | JAK/STAT3 and NF-κB | (5)     |
| LINC00974  | fBMFs         | -                           | OSF           | Increase myofibroblasts activation                                      | -               | TGF-β/Smad                                      | (55)    |
| HIF1A-AS1  | fBMFs         | -                           | OSF           | Increase myofibroblasts activation                                      | -               | -                                               | (53)    |
| GAS5-AS1   | fBMFs         | Arecoline                   | OSF           | Inhibit myofibroblasts activities in OSF                                | Inhibiting p-Smad and α-SMA | TGF-β/Smad                                      | (54)    |
| DQ786243   | CD4+ Treg cells | -                           | OLP           | Suppress the function of CD4+ T cells such as Th1 and Th17             | Elevating Foxp3 | miR-146a/NF-κB                                 | (63)    |
| HAS2-AS1   | Human OSCC cell lines | Hypoxia                  | OSCC          | Mediate hypoxia-induced EMT and invasiveness of OSCC                    | Stabilizing HAS2 | HF-1α and NF-κB                                 | (69)    |
| LINC01133  | Human OSCC cell lines | -                           | OSCC          | Inhibit OSCC cell migration and invasion                               | -               | GDF15                                           | (70)    |
| FOXCUT     | Human OSCC cell lines | -                           | OSCC          | Promote OSCC proliferation and migration ability                        | -               | FOXC1                                           | (71)    |
| MALAT1     | Human OSCC cell lines | -                           | OSCC          | Accelerates EMT and development of OSCC                                | Sponging miR-125b | STAT3                                          | (73)    |
| UCA1       | Human OSCC cell lines | -                           | OSCC          | Facilitate proliferation, enhance CDDP chemoresistance, and suppresses apoptosis | Sponging miR-184 | SF1                                             | (74)    |
| HOTAIR     | Human OSCC cell lines | -                           | OSCC          | Promote occurrence, invasion and metastasis                            | EZH2 and H3K27me3 | E-cadherin                                     | (76)    |

Inc, long non-coding; miR, microRNA; PDLCs, periodontal ligament cells; HGFs, human gingival fibroblasts; SGECs, salivary gland epithelial cells; fBMFs, fibrotic buccal mucosal fibroblasts; OSCC, oral squamous cell carcinoma; OLP, oral lichen planus; OSF, oral submucous fibrosis; SS, Sjögren’s syndrome; LPS, lipopolysaccharide; IFN, interferon; HIF1-α, hypoxia-inducible factor 1-α; Mirt2, myocardial infarction associated transcript 2; FGD5-AS1, FGD5 antisense RNA 1; MALAT1, metastasis associated lung adenocarcinoma transcript 1; HOTAIR, HOX transcript antisense RNA; TLR4, Toll-like receptor 4; HAS2, hyaluronan synthase 2; FOXC1, Fork head box C1; SOCS6, suppressor of cytokine signaling 6; NF-κB, nuclear factor-κ B; TGF-β, transforming growth factor-β; EMT, epithelial-mesenchymal transition; CDDP, cis-diamine dichloroplatinum; p, phosphorylated.
LncRNAs could transcriptionally regulate the progression of OSCC via interactions with proteins or activation of pathways with RNA and DNA molecules (85). Zhu et al. (89) verified that hypoxia induces the overexpression of hyaluronan synthase 2 antisense 1 (HAS2-AS1) in a HIF-1α-dependent manner. HAS2-AS1 mediates hypoxia-induced EMT and invasiveness of OSCC cells by binding and stabilizing the HAS2 gene. Additional research found that LINC01133 inhibited OSCC cell migration and invasion by inhibiting growth and differentiation factor 15 (GDF15) protein expression and formed a feedback regulatory loop with GDF15 (90). Kong et al. (91), found that expression of lncRNA FOXC1 upstream transcript, which is the adjacent promoter upstream of the Fork head box C1 (FOXC1) gene, was positively correlated with FOXC1 mRNA expression and promoted OSCC proliferation and migration. Thus, a vast amount of research has elucidated transcriptional regulatory mechanisms to address the role of lncRNAs in OSCC.

Posttranscriptional regulation through pre-mRNA alternative splicing, mRNA decay acceleration, mRNA protection, or translational activation or repression is also one of the primary mechanisms of IncRNAs (92). Chang and Hu (93), demonstrated that MALAT1 could function as a ceRNA to mediate STAT3 expression by sponging miR-125b in OSCC. OSCC cell viability and growth were enhanced by increasing expression levels of MALAT1, and a role of MALAT1/miR-125b/STAT3 axis was confirmed in vivo using a nude mouse xenograft model with OSCC Tca8113 cells. Fang et al. (94), found that lncRNA urothelial cancer associated 1 (UCA1) facilitated proliferation, enhanced cisplatin chemoresistance, and suppressed apoptosis in OSCC cells by suppressing miR-184 expression to increase the mRNA expression levels of splicing factor 1. Thus, ceRNA appears to be a promising posttranscriptional regulatory mechanism in OSCC.

In addition, lncRNAs could affect the characteristics of OSCC through epigenetic modifications, including DNA methylation, chromatin modification and imprinting (95). LncRNA HOX transcript antisense RNA (HOTAIR) repressed the expression of E-cadherin by binding to enhancer of zeste homolog 2, the enzymatic component of polycomb
repressive complex 2 (PRC2) and H3K27me3 at the E-cadherin promoter (96). HOTAIR silenced transcription factors by interacting with PRC2, lysine-specific histone demethylase-1 and RE-1 elements, leading to chromatin remodelling, thus trans-inhibiting the expression of the homeobox D cluster gene and promoting the occurrence, invasion and metastasis of tumors (96). Additional lncRNAs, participating in the progression of OSCC through epigenetic modifications, are expected to be detected, as there is an increasing number of the research being performed (95,97).

Accumulating evidence has shown that lncRNAs modulate the metastasis, proliferation, invasiveness and migration of oral cancer, especially OSCC, in cellular physiological processes (86,98,99). As aforementioned, lncRNAs interact with different cellular macromolecules, including chromatin, protein and RNA (36). According to the aforementioned studies, unstimulated OSCC cell lines are typically used for external models. Animal models are also well-established to provide more convincing evidence to confirm the role of lncRNAs in OSCC (89,93,94). This suggests that lncRNAs have the potential to be prognostic and therapeutic markers, providing valid approaches for clinical treatment.

6. Conclusion

With the advent of genomic technologies, including microarrays and RNA sequencing, investigations of lncRNA genomic profiles have been widely performed in the last 5 years (6,100,101). A large number of studies include microarray analyses of clinical tissue samples, which enhances the clinical value and significance of the findings (48,55,88). The present review not only summarized the lncRNA profiles but also elucidated the potential underlying mechanisms of lncRNAs in oral diseases (Table II and Fig. 3). These mechanisms may be significant to the clinical diagnosis and therapy of oral diseases. Moreover, the present review focused on the identification and associations of oral inflammatory disorders, PPOELs and OSCC and discussed the functions of lncRNAs in the pathophysiological process. By summarizing the studies involving the mechanisms of lncRNAs in oral diseases, ceRNA regulation was found to be the most common, while lncRNAs interacting with proteins is relatively rare. Thus, additional research is required to expand the early findings and characterize the mechanisms of DE lncRNAs. Overall, lncRNAs, the novel candidates in oral inflammatory disorders, PPOELs and oral cancer, should be investigated further, and their diagnostic and therapeutic functions may have significant value.

Acknowledgements

Not applicable.

Funding

This study was supported by the National Natural Science Foundation of China (grant nos. 81600882 and 81870755), a China Postdoctoral Science Foundation funded project (grant no. 2019M663009) and the President Foundation of Nanfang Hospital, Southern Medical University (grant no. 2019B002).

Availability of data and materials

Not applicable.

Authors' contributions

FF and BW contributed to the conception and design of the review. KZ contributed to the writing and drafting of the manuscript. FF and WQ contributed to the critical revision of the manuscript for important intellectual content. All the authors have given approval of the final version to be published and agree to be accountable for all aspects of the work.

Ethics approval and consent to participate

Not applicable.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References

1. Brogden KA, Johnson GK, Vincent SD, Abbati T and Vali S: Oral inflammation, a role for antimicrobial peptide modulation of cytokine and chemokine responses. Expert Rev Anti Infect Ther 11: 1097-1113, 2013.
2. Grivennikov SI, Greten FR and Karin M: Immunity, inflammation, and cancer. Cell 140: 883-899, 2010.
3. Kulikarni V, Uttamani JR, Naqvi AR and Nares S: microRNAs: Emerging players in oral cancers and inflammatory disorders. Tumour Biol 39: 1010428317698379, 2017.
4. Chen H, Lan Z, Li Q and Li Y: Abnormal expression of long noncoding RNA FGDS-AS1 affects the development of periodontitis through regulating mir-142-3p/SCOS6/NF-kB pathway. Artif Cells Nanomed Biotechnol 47: 2098-2106, 2019.
5. Xin M, Liang H, Wang H, Wen D, Wang L, Zhao L, Sun M and Wang J: Mirt2 functions in synergy with miR-377 to participate in inflammatory pathophysiology of sjogren's syndrome. Artif Cells Nanomed Biotechnol 47: 2473-2480, 2019.
6. Li S, Liu X, Li H, Pan H, Acharya A, Deng Y, Yu Y, Haak R, Schmidt J, Schmalz G and Ziebolz D: Integrated analysis of long noncoding RNA-associated competing endogenous RNA network in periodontitis. J Periodontal Res 53: 495-505, 2018.
7. Li J, Wang M, Song L, Wang X, Lai W and Jiang S: LncRNA MALAT1 regulates inflammatory cytokine production in lipopolysaccharide-stimulated human gingival fibroblasts through sponging miR-20a and activating TLR4 pathway. J Periodontal Res 55: 182-190, 2020.
8. Lee PH, Chu PM, Hsieh PL, Yang HW, Chueh PJ, Huang YF, Liao YW and Yu CC: Glabridin inhibits the activation of myofibroblasts in human fibrotic buccal mucosal fibroblasts through TGF-β/smads signaling. Environ Toxicol 33: 248-255, 2018.
9. Ganesh D, Sreenivasan P, Ohman J, Wallström M, Braz-Silva PH, Giglio D, Kjeller G and Hasséus B: Potentially malignant oral disorders and cancer transformation. Anticancer Res 38: 3223-3229, 2018.
10. Awadallah M, Idle M, Patel K and Kademani D: Management update of potentially premalignant oral epithelial lesions. Oral Surg Oral Med Oral Pathol Oral Radiol 125: 628-636, 2018.
11. Han X, Wei YB, Tian G, Tang Z, Gao JY and Xu XG: Screening of crucial long non-coding RNAs in oral epithelial dysplasia by serial analysis of gene expression. Genet Mol Res 14: 11729-11738, 2015.
12. Chen L, Zhou Y and Li H: LncRNA, miRNA and lncRNA-miRNA interaction in viral infection. Virus Res 257: 25-32, 2018.
13. Chattopadhyay E, Singh R, Ray A, Roy R, Sarkar ND, Paul RR, Pal M, Aich R and Roy B: Expression deregulation of mir31 and CXCL12 in two types of oral precancers and cancer: Importance of analog analysis of precancer and cancer. Sci Rep 6: 23275, 2016.

14. Fiori T and Ciarapica P: Oxidative stress, tumor microenvironment, and metabolic reprogramming: A diabolic liaison. Int J Cell Biol 2012: 762852, 2012.

15. Naylor MS, Stamp GW, Foulkes WD, Eccles D and Balkwill FR: Tumor necrosis factor and its receptors in human ovarian cancer. Potential role in disease progression. J Clin Invest 91: 2194-2206, 1993.

16. Yang G, Lu X and Yuan L: lncRNA: A link between RNA and cancer. Biochem Biophys Acta 1837: 1097-1109, 2014.

17. Yang ZH, Dang YQ and Ji G: Role of epigenetics in transformation of oral inflammation into colorectal cancer. World J Gastroenterol 25: 2863-2877, 2019.

18. Katsanos KH, Roda G, Brygo A, Delaporte E and Colombel JF: Oral cancer and oral precancerous lesions in inflammatory bowel diseases: A systematic review. J Crohns Colitis 9: 1045-1052, 2015.

19. Jia H, Wang X and Sun Z: Exploring the long noncoding RNAs-based biomarkers and pathogenesis of malignant transformation from dysplasia to oral squamous cell carcinoma by bioinformatics method. Eur J Cancer Prev 29: 174-180, 2021.

20. Camacho CV, Clauder‑Münster S, Pal M, Aich R and Roy B: Expression deregulation of mir31 and CXCL12 in two types of oral precancers and cancer: Importance of analog analysis of precancer and cancer. Sci Rep 6: 23275, 2016.

21. Zhang J and Chu M: Targeting of IL-6 relevant long noncoding RNA profiles in inflammatory and tumorous disease. Inflammation 42: 1139-1146, 2019.

22. St LG, Wahlestedt C and Kapranov P: The landscape of long noncoding RNA classification. Trends Genet 31: 239-251, 2015.

23. Jarrous J, Morillon A and Pinskaya M: History, discovery, and classification of lncRNAs. Adv Exp Med Biol 1008: 1-46, 2017.

24. Katsanos KH, Roda G, Brygo A, Delaporte E and Colombel JF: Oral cancer and oral precancerous lesions in inflammatory bowel diseases: A systematic review. J Crohns Colitis 9: 1045-1052, 2015.

25. Beltrami C, Angelini TG and Emanuelli C: Noncoding RNAs in plants. Front Genet 9: 168, 2018.

26. Bianchessi V, Badi I, Bertolotti M, Nigro P, D’Alessandra Y, Capogrossi MC, Zanobini M, Pompilio G, Raucci A and Laur A: The exosome component Rrp6 is required for RNA polymerase II termination at specific targets of the Nrd1-Nab3 pathway. PLoS Genet 11: e1004999, 2015.

27. Xu Z, Wei W, Gagneur J, Perocchi F, Clauder‑Münster S, Pal M, Aich R and Roy B: Expression deregulation of mir31 and CXCL12 in two types of oral precancers and cancer: Importance of analog analysis of precancer and cancer. Sci Rep 6: 23275, 2016.

28. Fiori T and Ciarapica P: Oxidative stress, tumor microenvironment, and metabolic reprogramming: A diabolic liaison. Int J Cell Biol 2012: 762852, 2012.
61. Zhou S, Zhu Y, He Z, Zhang D, Guo F, Jian X and Zhang C: Long non-coding RNA expression profile in minor salivary gland of primary Sjögren's syndrome. Arthritis Res Ther 18: 109, 2016.

62. Dolomino M, Tinazzi E, Vitali C, Del PN, Puccetti A and Lunardi C: Long non-coding RNAs modulate Sjögren's syndrome associated gene expression and are involved in the pathogenesis of the disease. J Clin Med 8: 1349, 2019.

63. Shi H, Cao N, Xie L, Zheng L and Yu C: Long non-coding RNA expression profile in the oral lichen planus. Oral Surg Oral Med Oral Pathol Oral Radiol 123: 235-241, 2017.

64. Jia B, Qiu X, Chen J, Sun X, Zheng X, Zhao J, Li Q and Wang Z: A feed-forward regulatory network IncpCATI/miR-106a-5p/E2F5 regulates non-ostogenic differentiation of periodontal ligament stem cells. J Cell Physiol 234: 19523-19538, 2018.

65. Huang Y, Han Y, Guo R, Liu H, Li X, Jia L, Zheng Y and Li W: Long non-coding RNA FERL14 promotes osteogenic differentiation of human periodontal ligament stromal cells via miR-874-3p and vascular endothelial growth factor A. Stem Cell Res Ther 11: 5, 2020.

66. Wang L, Wu F, Song Y, Li X, Wu Q, Duan Y and Jin Z: Long non-coding RNA related to periodontitis interacts with miR-182 to upregulate osteogenic differentiation in periodontal mesenchymal stem cells of periodontitis patients. Cell Death Dis 7: e2332, 2016.

67. Canniff JP, Harvey W and Harris M: Oral submucous fibrosis: Its pathogenesis and management. Br Dent J 160: 429-434, 1986.

68. Tilakaratne WM, Klinikowski MF, Saku T, Peters TJ and Holmstrup P: Update on oral lichen planus and oral squamous cell carcinoma. Medicine (Baltimore) 96: e7012, 2017.

69. Fang CY, Yu CC, Liao YW, Hsieh PL, Lu MY, Lin KC, Wu CZ and Tseng YK, Shiue YL, Ger LP and Tsai KW: Aberrant DNA hypermethylation-silenced SOX21-AS1 gene expression and its clinical importance in oral cancer. Clin Epigenetics 8: 129, 2016.

70. Arakeri G, Patil SG, Aljabab AS, Lin KC, Merkx MAW, Gao S and Brennan PA: Oral submucous fibrosis: An update on pathophysiology of malignant transformation. J Oral Pathol Med 46: 413-417, 2017.

71. Sharma M, Shetty SS and Radhakrishnan R: Oral submucous fibrosis as an healing wound: Implications in malignant transformation. Recent Pat Anticancer Drug Discov 13: 272-291, 2018.

72. Wu Y, Zhang L, Wang Y, Li H, Ren X, Wei F, Yu W, Liu T, Wang X, et al.: Long non-coding RNA LINC01135 inhibits oral squamous cell carcinoma metastasis through a feedback regulation loop with GDF15. J Surg Oncol 118: 1326-1334, 2018.

73. Kong X, Yao J, Luo W, Feng FK, Ma JT, Ren YP, Wang DL and Bu R: The expression and functional role of a FOX1 related miRNA-IncRNA pair in oral squamous cell carcinoma. Mol Cell Biochem 394: 177-186, 2014.

74. Li Y, Zhang J, Pan J, Feng X, Duan P, Yin X, Yu W, Yang Z and Zou S: Insights into the roles of IncRNAs in skeletal and dental diseases. Cell Biosci 8: 8, 2018.

75. Chang SM and Hu WW: Long non-coding RNA MALAT1 promotes oral squamous cell carcinoma development via microRNA-125b/STAT3 axis. J Cell Physiol 233: 3384-3396, 2018.

76. Fang Z, Zhao J, Xie W, Sun Q, Wang H and Qiao B: LncRNA UCA1 promotes proliferation and cisplatin resistance of oral squamous cell carcinoma by upregulating miR-184 expression. Cancer Med 6: 2897-2908, 2017.

77. Gonzalez-Ramirez I, Soto-Reyes E, Sanchez-Perez Y, Herrera LA and Garcia-Cuellar C: Histones and long non-coding RNAs: The new insights of epigenetic deregulation involved in oral cancer. Oral Oncol 56: 691-695, 2020.

78. Wu Y, Zhang L, Zhang X, Wang Y, Li H, Ren X, Wei F, Yu W, Liu T, Wang X, et al.: Long non-coding RNA HOTAIR promotes tumor cell invasion and metastasis by recruiting EZH2 and repressing E-cadherin in oral squamous cell carcinoma. Int J Oncol 46: 2856-2864, 2020.

79. Yang ZM, Wang TH, Chen HC, Li SC, Lee MC, Liou HH, Liu PF, Tseng YK, Shieue YL, Ger LP and Tsai KW: Ablant DNA hypermethylation-silenced SOX21-AS1 gene expression and its clinical importance in oral cancer. Clin Epigenetics 8: 129, 2016.

80. Shao TR, Zhang ZN, Chen YC, Wu QQ, Huang GZ, Li F, Zeng WS and Lv XZ: LncRNA AGO07271.3 promotes cell proliferation, invasion, migration and inhibits cell apoptosis of OSCC via the Wnt/b-catenin signaling pathway. Life Sci 239: 110787, 2019.

81. Chen F, Qi S, Zhang X, Wu J, Yang X and Wang R: LncRNA PLAC2 activated by H3K27 acetylation promotes cell proliferation and invasion via the activation of Wnt/b-catenin pathway in oral squamous cell carcinoma. Int J Oncol 54: 1138-1139, 2019.

82. Meseure D, Drak AK, Nicolas A, Bieche I and Morillon A: Long noncoding RNAs as new architects in cancer epigenetics, prognostic biomarkers, and potential therapeutic targets. BioMed Res Int 2015: 320214, 2015.

83. Yu H, Zhang L, Mao L, Wu Y, Liu S, Ruan M, Hu J and Ren G: A comprehensive genome-wide analysis of the long noncoding RNA expression profile in metastatic lymph nodes of oral mucosal melanoma. Gene 675: 44-53, 2018.